ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
31 announcements
Corona Remedies received an NPPA demand notice of Rs 4.88 Crore for alleged DPCO 2013 price violations. The company is evaluating it and reports no material financial impact.
CORONA delivered robust revenue growth of 22% YoY, outperforming the Indian pharmaceutical market by focusing on chronic segments. Management maintains a growth target of 1.5x the market rate.
Q2FY27 revenue ₹441.2Cr (+22.2%), PAT ₹60.3Cr (+15.3%); H1 revenue ₹863.6Cr (+22.0%), PAT ₹120.4Cr (+22.2%). Chronic-led growth, outpacing IPM.
Corona Remedies released unaudited Q2 and H1 FY27 results highlights via press release. Revenue grew 22% year on year, with EBITDA and PAT also rising.
Corona Remedies Ltd reported revenue from operations of ₹441.2 Cr (+22.2% YoY) and net profit of ₹60.3 Cr (+15.3% YoY) for Q2 FY27.
Corona Remedies received GMP Compliance Certification from Brazil's ANVISA for its OSD and Hormone facilities in Ahmedabad. This validates export eligibility to the Brazilian pharmaceutical market.
Corona Remedies Limited will hold a board meeting on October 30, 2026. The board will consider unaudited financial results for the quarter and half-year ended September 30, 2026.
This filing contains quarterly shareholding pattern disclosures for Corona Remedies Ltd. It provides details on share distribution as required by regulatory compliance norms.
CARE Ratings has reaffirmed and upgraded the credit ratings assigned to Corona Remedies Limited's bank facilities, as disclosed in the latest regulatory filing.
Sepia Investments Limited, Sage Investment Trust, and Anchor Partners sold 2,629,880 equity shares of Corona Remedies Limited. This non-promoter stake sale is disclosed under SEBI SAST regulations.
CORONA Remedies Limited clarified that the recent increase in its share trading volume is purely market-driven and no undisclosed price-sensitive information exists.
Corona Remedies reported robust Q1 FY27 results with 21.9% revenue growth and 33.5% EBITDA growth. Strategy focuses on chronic therapies and scaling brand portfolios.
Corona Remedies reported strong Q1FY27 performance with 21.9% revenue growth and 33.5% EBITDA growth, driven by its strategic shift towards chronic therapies which now contribute ~73.4% of revenue.
CORONA Remedies reported Q1FY27 Revenue of ₹422.4 Crore, up 21.9% Y-o-Y, and PAT of ₹60.1 Crore, up 30.1% Y-o-Y, highlighting resilient growth.
Corona Remedies Ltd reported revenue from operations of ₹422.4 Cr (+21.9% YoY) and net profit of ₹60.1 Cr (+30.1% YoY) for Q1 FY27.
Corona Remedies scheduled a board meeting on July 31, 2026. The board will consider unaudited quarterly financial results for the period ended June 30, 2026.
CORONA Remedies Limited held its 22nd AGM on July 9, 2026, approving a final dividend of ₹10 per share. The meeting also appointed directors and auditors.
Corona Remedies commenced commercial production at its EU-GMP approved Women's Hormone facility. The plant has an annual capacity of 194 million tablets/capsules.
Corona Remedies scheduled its 22nd AGM for July 9, 2026. Agenda includes a ₹10 dividend declaration and ₹1 Crore remuneration for Dr. Kirtikumar Mehta.
Corona Remedies Ltd filed its Annual Report for FY 2025-26 with the exchanges. The report details the company's financial performance and strategic milestones for the year.
Corona Remedies received EU-GMP certification for its Hormone facility and renewed approval for its OSD plant. These accreditations support the company's global pharmaceutical market expansion.
Corona Remedies reported strong FY26 results, outperforming industry growth via specialty chronic segments and strategic acquisitions like Wokadine and the Bayer portfolio.
Corona Remedies Ltd filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory compliance with SEBI norms.
CORONA Remedies reported 17.3% FY26 revenue growth to ₹1,403.2 Cr, driven by chronic therapy focus and strategic acquisitions like Wokadine. Company maintain's 20.9% EBITDA margins.
Corona Remedies recommended a 100% final dividend for the 2025-26 period. The board fixed June 19, 2026, as the record date for payment eligibility.
CORONA Remedies approved several key auditor appointments and director re-appointments during its board meeting. These leadership updates ensure continued regulatory compliance and statutory oversight.
Corona Remedies Ltd reported revenue from operations of ₹353.1 Cr (+20.2% YoY) and net profit of ₹45.3 Cr (+43.4% YoY) for Q4 FY26.
CORONA Remedies reported FY26 revenue of ₹1,403.2 Crore, representing 17.3% growth. PAT grew 33.4%, driven by strong brand building and the WOKADINE acquisition.
CORONA Remedies reported FY26 total standalone income of ₹1,413.83 Crore. The Board recommended a 100% final dividend of ₹10 per equity share.
CORONA Remedies Limited has scheduled a board meeting on May 11, 2026. The board will consider and approve audited standalone and consolidated financial results for the year ended March 31, 2026, and recommend a final dividend. The trading window has been closed since April 1, 2026.